Julius Quinn
Psychiatric/Mental Health · Wichita, KSNPI 1073883815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 513 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 513 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$700
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$680
- Corium, LLC$667
- plus $4K from 21 others
What the payments were for
- Food & beverage$9,84099%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 81 | $1,802 |
| AbbVie(2 entities) | 97 | $1,174 |
| Alkermes, Inc. | 42 | $1,131 |
| Vanda Pharmaceuticals Inc. | 24 | $700 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $680 |
| Corium, LLC | 49 | $667 |
| Teva Pharmaceuticals USA, Inc. | 25 | $534 |
| Ironshore Pharmaceuticals Inc. | 25 | $456 |
| Lundbeck LLC | 17 | $325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $300 |
| Axsome Therapeutics, Inc. | 11 | $298 |
| Supernus Pharmaceuticals, Inc. | 22 | $278 |
| Neos Therapeutics, LP | 14 | $241 |
| Lilly USA, LLC | 10 | $164 |
| Neurocrine Biosciences, Inc. | 9 | $152 |
| Indivior Inc. | 7 | $149 |
| Novo Nordisk | 2 | $145 |
| Amgen | 1 | $125 |
| Tris Pharma Inc | 7 | $123 |
| Johnson & Johnson | 7 | $118 |
| Noven Therapeutics, LLC | 4 | $90 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
| Vertical Pharmaceuticals, LLC | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Bayer | 1 | $20 |
| Biogen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,897 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $35,678 |
| OzempicSemaglutide | 24 | $19,429 |
| NeuproRotigotine | 11 | $9,578 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,741 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,634 |
| Lisdexamfetamine Dimesylate | 12 | $3,191 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 46 | $2,989 |
| Aripiprazole | 17 | $2,894 |
| Methylphenidate Er (La)Methylphenidate Hcl | 19 | $2,524 |
| Trazodone Hcl | 56 | $1,115 |
| Vilazodone Hcl | 13 | $830 |
| Methylphenidate Hcl | 14 | $639 |
| Buspirone Hcl | 17 | $506 |
| Bupropion XlBupropion Hcl | 27 | $491 |
| Rosuvastatin Calcium | 15 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $118 | $35,67814 claims |
| Novo NordiskOzempic | $145 | $19,42924 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $300 | $11,37526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Wichita
- Hayley KnappWichita$31K
- Deborah MurphyWichita$13K
- Ashley MeluginWichita$9K
- Jacy BarkerWichita$9K
- Susan MilehamWichita$8K
- Angela TheobaldWichita$6K
- Alyson Taylor-SmithWichita$5K
- Ruth HartWichita$5K
- Julia McVayWichita$5K
- Amy AdamsWichita$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.